CRSP77 Inhibitors

CRSP77 inhibitors encompass a diverse range of chemical compounds that indirectly affect the activity of MED17, a key component of the mediator complex in transcription regulation. These inhibitors achieve their effects through various mechanisms, impacting different stages of the transcription process and the stability of transcription-related proteins. For instance, Triptolide and α-Amanitin target the general transcription machinery and RNA polymerase II, respectively. By inhibiting these components, they could indirectly affect MED17's role in transcription initiation and elongation. Other compounds like DRB and Flavopiridol target the elongation phase of transcription. DRB inhibits RNA polymerase II elongation, while Flavopiridol inhibits CDK9, a critical kinase in transcription elongation. These actions can indirectly impact MED17 function in the mediator complex. Rocaglamide and Actinomycin D affect protein synthesis and DNA binding, respectively, potentially reducing MED17's effectiveness in transcription regulation. BET bromodomain inhibitors like I-BET151 and JQ1 modulate transcription processes, indirectly influencing MED17's role.